Inhibitory activities of phenylpropanoids from Lycopus lucidus on amyloid aggregation related to Alzheimer's disease and type 2 diabetes.
Alzheimer’s disease
Amyloid β
Human islet amyloid polypeptide
Lycopic acids
Schizotenuin A
Type 2 diabetes
Journal
Journal of natural medicines
ISSN: 1861-0293
Titre abrégé: J Nat Med
Pays: Japan
ID NLM: 101518405
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
04
10
2019
accepted:
09
03
2020
pubmed:
29
3
2020
medline:
28
7
2020
entrez:
29
3
2020
Statut:
ppublish
Résumé
The number of patients with Alzheimer's disease (AD) and type 2 diabetes (T2D) is increasing rapidly, and thus more research has been focused on the relationship between these two age-related chronic diseases. According to the amyloid hypothesis, prevention of the aggregation of amyloid β (Aβ) and human islet amyloid polypeptide (hIAPP) is a promising strategy for AD and T2D. In this study, thioflavin-T assay and transmission electron microscopy were performed to evaluate the inhibitory effect of three phenylpropanoids isolated from Lycopus lucidus-schizotenuin A and lycopic acids A and B-on both Aβ and hIAPP fibrillization. All tested compounds exhibited similarly strong inhibitory activity toward amyloid aggregation. These results suggested that catechol moieties play important roles in the inhibition of amyloid plaque formation.
Identifiants
pubmed: 32219646
doi: 10.1007/s11418-020-01398-6
pii: 10.1007/s11418-020-01398-6
doi:
Substances chimiques
Amyloid beta-Peptides
0
Catechols
0
Islet Amyloid Polypeptide
0
Plant Extracts
0
catechol
LF3AJ089DQ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
579-583Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP24580156